Posted on Leave a comment

Alembic Pharma FY2019 net sales rises to 32%

Vadodara January 22nd, 2019

Alembic Pharmaceuticals Limited reported its financial results for the third quarter ending 31st December 2018.

Financial Highlights – Consolidated

·         Net Sales for the quarter up 21% to Rs 1018 crores from Rs. 840 crores.

·         Net Profit for the quarter up 25% to Rs 162 crores

·         Net sales for FY19 up 32% to Rs 3008 crores against Rs 2277 crores last year.

·         Net profit for FY19 up 47% to Rs 467 crores from Rs 317 Crores last year.

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said “The growth in the quarter was attributed to a strong performance in the US and International business. Our Formulation as well as API Facilities were successfully approved by the US FDA during the quarter”.

Operational Highlights for the quarter

International Business

·         International Formulations grew 44% to Rs 448 crores for the quarter.

·         The US business grew by 42% to Rs 308 crores for the quarter

·         7  ANDA  approvals received during the quarter, 83 Cumulative ANDA approvals.

·         3 new products launched in the US market.

·         4 ANDA filings during the quarter, Cumulative ANDA filings at 147.

·         R&D spend at Rs 112 Crores for the quarter, 11% of Sales.

India Formulations Business

·         India formulations business for the quarter grew by 4% to Rs 365 crores as against Rs. 349 crores last year.

API Business

·         API Business for the quarter grew by 14% to Rs 205 Crores as against Rs 180 Crores last year.

Summary of Total Revenue is as under:   

(Rs in Crores)

Particulars

Q3 FY19

Q3 FY18

% Change

9M FY19

9M FY18

% Change

Formulation

USA

ROW

308

140

218

93

42%

50%

945

442

605

249

56%

77%

India                            

365

349

4%

1080

970

11%

API

205

180

14%

540

453

19%

Total

1018

840

21%

3008

2277

32%

                                         

The Profit break-up is as under:                              

(Rs in Crores)

Particulars

Q3 FY19

Q3 FY18

% Change

9M FY19

9M FY18

% Change

EBITDA Pre R&D

351

281

25%

1061

755

41%

EBITDA Pre R&D %

34%

34%

35%

33%

EBITDA Post R&D

245

188

31%

701

477

47%

EBITDA Post R&D %

24%

22%

23%

21%

Profit Before Tax

211

161

31%

603

400

51%

Net Profit after Tax

162

130

25%

467

317

47%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at  www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai

Phone: +91 22 – 306 11681

Mitanshu Shah  

Phone: +91 265 – 3007630

For more information Contact
Maulikk Buch
Chief Publicist
REOPINION
99783389999

22.307158873.1812187